Extension Study of Protocol EV-BR1701 Group B1
Long-Term Immunogenicity Study of an Adjuvanted, Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children: An Extension Study of Protocol EV-BR1701 Group B1
The main study was a randomized, multi-nation, multi-centered, double-blinded, phase III study on subjects aged 2 months to <6 years old (<72 months). Two parts were conducted in Taiwan (Group A) and Vietnam (Group B). This extended study involved the subjects enrolled in the EV-BR1701 Group B1 who received any IP injections. For Group B, out of 2727 subjects enrolled from June 2022 to Jul 2023, 241 subjects of Group B1 would be assigned to this extension study. The extension study aimed to evaluate the immunogenicity persistence after EnVAX-A71 vaccination.
The subjects of Group B1 would be recalled for phlebotomy and immunogenicity analysis. The subjects would not receive further study EV71 vaccines in the extension study.
The principal investigators (PIs) and study coordinators (SCs) of the original medical center would contact the subject's guardians/legal representative by phone to return to the medical center for phlebotomy.
Informed consent would be provided to the guardians/legal representative of the subjects, and the eligibility of subjects would be verified on the day of the recall visit.
After the subject was evaluated by the PI and meets the phlebotomy requirements, the subject's guardian/legal representative would be asked to sign the informed consent form, and the new subject's number would be given.
About 3-4 mL of blood would be collected from each subject, and the serum would be collected and sent to the designated central laboratory for testing. The validated neutralizing antibody (NTAb) analysis method would be used to determine the neutralizing antibody titer.
The NTAb titer results would be directly sent to the CRO Data Manager Team, and statistical analysis for immunogenicity would be performed and reported after the main study was complete.
調査の概要
状態
条件
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Vinh Long Province
-
Vĩnh Long、Vinh Long Province、ベトナム
- Centers for Disease Control and Prevention, Vinh Long Province, Vietnam
-
-
参加基準
適格基準
就学可能な年齢
- 子
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
The main study is a randomized, multi-nation, multi-centered, double-blinded, phase III study on subjects aged 2 months to <6 years old (<72 months). Two parts are conducted in Taiwan (Group A) and Vietnam (Group B). This extended study involves the subjects enrolled in the EV-BR1701 Group B1 who received any IP injections. For Group B, out of 2727 subjects enrolled from June 2022 to Jul 2023, 241 subjects of Group B1 will be assigned to this extension study. The extension study aims to evaluate the immunogenicity persistence after EnVAX-A71 vaccination.
The subjects of Group B1 will be recalled for phlebotomy and immunogenicity analysis. The subjects will not receive further study EV71 vaccines in the extension study.
説明
Inclusion Criteria:
- Healthy children enrolled in group B1 of the EV-BR1701 study who received at least one dose of IP injection with the duration after the last vaccination from at least 2 years up to 2 years and 6 months.
- The subject's guardians are able and willing to comply with study procedures and provide signed informed consent.
Exclusion Criteria:
- Severe malnutrition or dysgenopathy at the screening visit.
- Bleeding disorder diagnosed by a doctor or significant bruising or hemostatic difficulties with IM injections or phlebotomy.
- Any condition in the investigator's opinion may interfere with evaluating study objectives.
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
This extension study aims to assess the long-term immunogenicity of EnVAX-A71 vaccination in children aged two months to under six years old.
時間枠:From Dec-2024 to Jan-2025
|
To determine the serum EV71-specific neutralizing antibody (NTAb) titers by measuring the GMT, SCRa, and SPRb for those subjects from Part B1 upon recall.
|
From Dec-2024 to Jan-2025
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Wendy Wu、Enimmune Corporation
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- EV-BR1701e
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。